PepGen stock drops after Phase 2 low-dose data show limited splicing correction; higher-dose cohorts and FDA hold remain key focus areas.
Importance Rank:
1
PepGen stock drops after Phase 2 low-dose data show limited splicing correction; higher-dose cohorts and FDA hold remain key focus areas.
Copyright © Louis Velazquez. All Rights Reserved.